SciELO - Scientific Electronic Library Online

 
vol.25 issue1Molecular aspects of ABO Blood Group SystemAmnaphtone in the treatment of nosebleed author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista Brasileira de Hematologia e Hemoterapia

Print version ISSN 1516-8484On-line version ISSN 1806-0870

Abstract

PAULA, Erich V. de; SAAD, Sara T. O.  and  COSTA, Fernando F.. Oral Iron chelation therapy in Beta-Thalassaemia. Rev. Bras. Hematol. Hemoter. [online]. 2003, vol.25, n.1, pp.59-63. ISSN 1516-8484.  http://dx.doi.org/10.1590/S1516-84842003000100009.

Iron chelation therapy with desferrioxamine (DFO) has dramatically improved the outlook in beta-thalassaemia patients. DFO reduces tissue iron stores, prevents iron-induced organ damage, and reduces morbidity and mortality. However, the need for prolonged subcutaneous portable pump infusions, high cost, and patient noncompliance have prompted the development of new iron chelators. Deferiprone, is the only oral iron chelator in clinical use and has been studied in large long-term clinical trials. Combination therapy with deferiprone and DFO has emerged as a new alternative for beta thalassaemia patients. Combination therapy may minimize side effects, improve compliance, enhance iron excretion and target specific iron pools. The availability of new chelating compounds and new methods for body-iron store evaluation may lead to individualized therapy in the future.

Keywords : Deferiprone; oral chelation; beta thalassemia.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf epdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License